{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:34:09Z","timestamp":1768563249866,"version":"3.49.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":4662,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1111\/j.1538-7836.2009.03701.x","type":"journal-article","created":{"date-parts":[[2009,11,23]],"date-time":"2009-11-23T23:27:02Z","timestamp":1259018822000},"page":"433-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential"],"prefix":"10.1016","volume":"8","author":[{"given":"V.J.","family":"MARDER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"NOVOKHATNY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0010","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/01.CIR.83.2.448","article-title":"Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in myocardial infarction, Phase\u00a0II, pilot and clinical trial","volume":"83","author":"Gore","year":"1991","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0015","doi-asserted-by":"crossref","first-page":"802","DOI":"10.7326\/0003-4819-90-5-802","article-title":"The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring","volume":"90","author":"Marder","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0020","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1056\/NEJM198806093182306","article-title":"Thrombolytic therapy: current status","volume":"318","author":"Marder","year":"1988","journal-title":"New Engl J Med"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1148\/111.1.31","article-title":"Selective clot lysis with low\u2010dose streptokinase","volume":"111","author":"Dotter","year":"1974","journal-title":"Radiology"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejvs.2006.11.013","article-title":"Treatment of acute iliofemoral deep venous thrombosis: a strategy of thrombus removal","volume":"33","author":"Comerota","year":"2007","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1749-6632.1957.tb42616.x","article-title":"Clinical and experimental studies on fibrinolytic enzymes","volume":"68","author":"Ambrus","year":"1957","journal-title":"Ann NY Acad Sci"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0040","first-page":"539","article-title":"Comparative effectiveness of intravenous and intra\u2010arterial fibrinolysis therapy","volume":"6","author":"Boyles","year":"1960"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0045","first-page":"525","article-title":"Segmental perfusion of the coronary arteries with fibrinolysis in man following a myocardial infarction","volume":"6","author":"Boucek","year":"1960"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0050","first-page":"546","article-title":"The treatment of cerebrovascular thromboses and embolism with fibrinolytic agents","volume":"6","author":"Clarke","year":"1960"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0055","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1172\/JCI103885","article-title":"The mechanism of clot dissolution by plasmin","volume":"38","author":"Alkjaersig","year":"1959","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/oxfordjournals.bmb.a070337","article-title":"Thrombolytic therapy","volume":"20","author":"Douglas","year":"1964","journal-title":"Br Med Bull"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0065","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0005-2795(79)90094-1","article-title":"On the specific interaction between the lysine\u2010binding sites in plasmin and complementary sites in alpha\u00a02\u2010antiplasmin and in fibrinogen","volume":"579","author":"Wiman","year":"1979","journal-title":"Biochim Biophys Acta"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-0038-1650023","article-title":"On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture","volume":"43","author":"Collen","year":"1980","journal-title":"Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1111\/j.1538-7836.2009.03701.x_bb0075","first-page":"109","article-title":"Thrombolysis in arterial occlusion","volume":"82","author":"Verhaeghe","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1051-0443(07)61420-1","article-title":"Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter directed peripheral arterial and venous thrombolysis","volume":"11","author":"Ouriel","year":"2000","journal-title":"J Vasc Interv Radiol"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0085","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1055\/s-0037-1616127","article-title":"Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit","volume":"86","author":"Marder","year":"2001","journal-title":"Thromb Haemost"},{"issue":"Suppl. 3","key":"10.1111\/j.1538-7836.2009.03701.x_bb0090","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.thromres.2008.06.018","article-title":"Structure and activity of plasmin and other direct thrombolytic agents","volume":"122","author":"Novokhatny","year":"2008","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0095","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.toxicon.2005.02.027","article-title":"Snake venom fibrin(ogen)olytic enzymes","volume":"45","author":"Swenson","year":"2005","journal-title":"Toxicon"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0100","first-page":"141","article-title":"Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis","volume":"31","author":"Toombs","year":"2001","journal-title":"Haemostasis"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0105","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/S0021-9258(18)95967-3","article-title":"The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin","volume":"242","author":"Robbins","year":"1967","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0110","unstructured":"Sottrup\u2010Jensen L, Claeys H, Zajdel M, Petersen TE, Magnusson S. The primary structure of human plasminogen: isolation of two lysine\u2010binding fragments and one \u2018mini\u2019 plasminogen (MW\u00a038000) by elastase\u2010catalyzed specific limited proteolysis. In: Davidson JF, Rowan RM, Samama MM, Desnoyers PC, Eds. Progress in chemical fibrinolysis and thrombolysis, vol. 3. New York: Raven Press, pp 191\u2013209."},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0115","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1016\/S0021-9258(17)33334-3","article-title":"Mechanism of the urokinase\u2010catalyzed activation of human plasminogen","volume":"251","author":"Violand","year":"1976","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1432-1033.1977.tb11578.x","article-title":"Primary structure of the B\u2010chain of human plasmin","volume":"76","author":"Wiman","year":"1977","journal-title":"Eur J Biochem"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0049-3848(77)90003-2","article-title":"The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen","volume":"10","author":"Wiman","year":"1977","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0130","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1016\/S0021-9258(18)32614-0","article-title":"The binding of human plasminogen to fibrin and fibrinogen","volume":"258","author":"Lucas","year":"1983","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00001721-199404000-00001","article-title":"The structure of recombinant plasminogen kringle\u00a01 and the fibrin binding site","volume":"5","author":"Wu","year":"1994","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0140","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1432-1033.1978.tb12200.x","article-title":"On the kinetics of the reaction between human antiplasmin and plasmin","volume":"84","author":"Wiman","year":"1978","journal-title":"Eur J Biochem"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0145","doi-asserted-by":"crossref","first-page":"13333","DOI":"10.1074\/jbc.M313164200","article-title":"A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis","volume":"279","author":"Schneider","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0150","first-page":"156","article-title":"The importance of intermediate degradation products of fibrinogen in fibrinolytic hemorrhage","volume":"80","author":"Marder","year":"1967","journal-title":"Trans Assoc Am Physicians"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0155","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0021-9258(18)94373-5","article-title":"High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization","volume":"244","author":"Marder","year":"1969","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0160","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1126\/science.160.3830.892","article-title":"Cross\u2010link in fibrin polymerized by factor\u00a013: epsilon\u2010(gamma\u2010glutamyl)lysine","volume":"160","author":"Pisano","year":"1968","journal-title":"Science"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0049-3848(75)90127-9","article-title":"Characterization of a soluble D\u00a0dimer\u2013E complex in crosslinked fibrin digests","volume":"7","author":"Gaffney","year":"1975","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0170","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1172\/JCI109931","article-title":"Plasmic degradation of cross\u2010linked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure","volume":"66","author":"Francis","year":"1980","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0033-0620(91)90010-J","article-title":"The plasminogen\u2013plasmin system","volume":"34","author":"Henkin","year":"1991","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0180","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1146\/annurev.me.37.020186.001155","article-title":"Concepts of clot lysis","volume":"37","author":"Francis","year":"1986","journal-title":"Annu Rev Med"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0185","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1126\/science.170.3962.1095","article-title":"Plasminogen: purification from human plasma by affinity chromatography","volume":"170","author":"Deutsch","year":"1970","journal-title":"Science"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0190","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0076-6879(93)23044-N","article-title":"Expression of human plasminogen cDNA in lepidopteran insect cells and analysis of asparagine\u2010linked glycosylation patterns of recombinant plasminogens","volume":"223","author":"Castellino","year":"1993","journal-title":"Methods Enzymol"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0195","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jvir.2009.03.043","article-title":"Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis","volume":"20","author":"Hoefer","year":"2009","journal-title":"J Vasc Interv Radiol"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0200","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1046\/j.1538-7836.2003.00128.x","article-title":"Thrombolytic potency of acid\u2010stabilized plasmin: superiority over tissue\u2010type plasminogen activator in an in\u00a0vitro model of catheter\u2010assisted thrombolysis","volume":"1","author":"Novokhatny","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0205","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.pep.2006.10.012","article-title":"Refolding, purification, and activation of miniplasminogen and microplasminogen isolated from E.\u00a0coli inclusion bodies","volume":"52","author":"Medynski","year":"2007","journal-title":"Protein Expr Purif"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0210","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood.V58.1.97.97","article-title":"Mini\u2010plasminogen: a mechanism for leukocyte modulation of plasminogen activation by urokinase","volume":"58","author":"Moroz","year":"1981","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0215","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1055\/s-0038-1650234","article-title":"Quantitative comparison of fibrin degradation with plasmin, miniplasmin, neurophil leukocyte elastase and cathepsin\u00a0G","volume":"75","author":"Kolev","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0220","doi-asserted-by":"crossref","first-page":"19658","DOI":"10.1016\/S0021-9258(17)45422-6","article-title":"Interaction of plasminogen and fibrin in plasminogen activation","volume":"265","author":"Wu","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0225","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1432-1033.1978.tb12360.x","article-title":"On the kinetics of the reaction between human antiplasmin and a low\u2010molecular\u2010weight form of plasmin","volume":"87","author":"Wiman","year":"1978","journal-title":"Eur J Biochem"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0230","first-page":"725","article-title":"Alpha\u00a02\u2010macroglobulin is the primary inhibitor of miniplasmin in\u00a0vitro and in\u00a0vivo in the mouse. Comparison with alpha\u00a02\u2010antiplasmin in simultaneous reaction experiments","volume":"255","author":"Gonias","year":"1988","journal-title":"Biochem J"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0235","doi-asserted-by":"crossref","first-page":"8793","DOI":"10.1073\/pnas.84.24.8793","article-title":"Structure and formation of microplasmin","volume":"84","author":"Wu","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0240","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/pro.5560040911","article-title":"Structure and function of microplasminogen: I. Methionine shuffling, chemical proteolysis, and proenzyme activation","volume":"4","author":"Wang","year":"1995","journal-title":"Protein Sci"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0245","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10529-006-9290-5","article-title":"Expression and characterization of recombinant human micro\u2010plasminogen","volume":"29","author":"Ma","year":"2007","journal-title":"Biotechnol Lett"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0250","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1538-7836.2003.00078.x","article-title":"Recombinant human microplasmin: production and potential therapeutic properties","volume":"1","author":"Nagai","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0255","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1160\/TH08-04-0225","article-title":"Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma\u2010derived plasmin","volume":"100","author":"Hunt","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0260","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/pro.5560010505","article-title":"Amino acid sequence of fibrolase, a direct\u2010acting fibrinolytic enzyme from Agkistrodon contortrix contortrix venom","volume":"1","author":"Randolph","year":"1992","journal-title":"Protein Sci"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0265","first-page":"147","article-title":"Biochemical characteristics of fibrolase, a fibrinolytic protease from snake venom","volume":"20","author":"Ahmed","year":"1990","journal-title":"Haemostasis"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0270","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/01.RVI.0000148828.40438.D3","article-title":"Cross\u2010species pharmacologic evaluation of plasmin as a direct\u2010acting thrombolytic agent: ex\u00a0vivo evaluation for large animal model development","volume":"16","author":"Landskroner","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0275","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1161\/STROKEAHA.107.507376","article-title":"Middle cerebral artery occlusion in the rabbit using selective angiography: application for assessment of thrombolysis","volume":"39","author":"Jahan","year":"2008","journal-title":"Stroke"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0280","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2002-08-2546","article-title":"Distinct dose\u2010dependent effects of plasmin and tPA on coagulation and hemorrhage","volume":"101","author":"Stewart","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0285","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1046\/j.1538-7836.2003.00441.x","article-title":"Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding","volume":"1","author":"Sadeghi","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0290","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.thromres.2008.06.019","article-title":"Preclinical studies of plasmin: superior benefit\u2010to\u2010risk ratio compared to tissue plasminogen activator (tPA)","volume":"122","author":"Marder","year":"2008","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0295","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.thromres.2008.01.007","article-title":"The thrombolytic effect of miniplasmin in a canine model of femoral artery thrombosis","volume":"122","author":"Fu","year":"2008","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0300","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1182\/blood.V97.10.3086","article-title":"Depletion of circulating alpha(2)\u2010antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization","volume":"97","author":"Nagai","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0305","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1161\/01.STR.0000028267.09604.7B","article-title":"Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits","volume":"33","author":"Lapchak","year":"2002","journal-title":"Stroke"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0310","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/j.1538-7836.2004.00889.x","article-title":"Comparative effects of microplasmin and tissue\u2010type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice","volume":"2","author":"Suzuki","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0315","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1161\/01.STR.0000140628.00927.1a","article-title":"Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI","volume":"35","author":"Suzuki","year":"2004","journal-title":"Stroke"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0320","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1148\/radiol.2442061316","article-title":"Microplasmin and tissue plasminogen activator: comparison of therapeutic effects in rat stroke model at multiparametric MR imaging","volume":"244","author":"Chen","year":"2007","journal-title":"Radiology"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0325","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1179\/016164107X181860","article-title":"Effects of microplasmin on recovery in a rat embolic stroke model","volume":"30","author":"Rasmussen","year":"2008","journal-title":"Neurol Res"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0330","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1167\/iovs.03-0930","article-title":"Posterior vitreous detachment induced by microplasmin","volume":"45","author":"Gandorfer","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0335","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.eye.6702931","article-title":"Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator","volume":"22","author":"Chen","year":"2008","journal-title":"Eye"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0340","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1167\/iovs.08-2185","article-title":"Microplasmin: ex\u00a0vivo characterization of its activity in porcine vitreous","volume":"50","author":"De Smet","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0345","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000092427","article-title":"Non\u2010clinical and clinical characterization of a novel acting thrombolytic: alfimeprase","volume":"34","author":"Deitcher","year":"2005","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0350","first-page":"329","article-title":"Drug evaluation: alfimeprase, a plasminogen\u2010independent thrombolytic","volume":"10","author":"Shah","year":"2007","journal-title":"IDrugs"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0355","doi-asserted-by":"crossref","first-page":"H959","DOI":"10.1152\/ajpheart.00649.2005","article-title":"Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs. alfimeprase","volume":"290","author":"Hong","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0360","unstructured":"U.S. National Institutes of Health. A service of the U.S. National Institutes of HealthClinicalTrials.gov, 2009."},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0365","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1538-7836.2008.02969.x","article-title":"A first\u2010in\u2010human phase\u00a0I trial of locally delivered human plasmin for hemodialysis graft occlusion","volume":"6","author":"Shlansky\u2010Goldberg","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 3","key":"10.1111\/j.1538-7836.2009.03701.x_bb0370","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.thromres.2008.06.012","article-title":"Development of catheter\u2010directed intrathrombus thrombolysis with plasmin for the treatment of acute lower extremity arterial occlusion","volume":"122","author":"Comerota","year":"2008","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0375","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00604816","article-title":"Lys\u2010plasminogen as an adjunct to local intra\u2010arterial fibrinolysis for carotid territory stroke: laboratory and clinical findings","volume":"38","author":"Freitag","year":"1996","journal-title":"Neuroradiology"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0380","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ajo.2004.05.024","article-title":"Intrasurgical plasmin enzyme in diabetic macular edema","volume":"138","author":"Azzolini","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0385","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1161\/STROKEAHA.109.560201","article-title":"Randomized, placebo\u2010controlled, dose\u2010ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke","volume":"40","author":"Thijs","year":"2009","journal-title":"Stroke"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0390","series-title":"Thrombogenics Announces Promising Results of MITI\u00a0IV Phase\u00a0II Trial in the Treatment of Acute Stroke with Microplasmin","year":"2008"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0395","series-title":"ThromboGenics NV Announces Update on its Microplasmin Development Strategy for Peripheral Vascular Disease. Development of Microplasmin for the Treatment of Acute Deep Vein Thrombosis Represents a More Attractive Commercial Opportunity","year":"2006"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0400","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11239-009-0310-x","article-title":"A pilot trial of microplasmin in patients with long\u2010term venous access catheter thrombosis","volume":"28","author":"Verhamme","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0405","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.ophtha.2009.03.051","article-title":"Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI\u00a0I trial","volume":"116","author":"De Smet","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0410","series-title":"ThromboGenics Reports Positive Results from Phase\u00a02b Trial of Microplasmin in Vitrectomy","year":"2008"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0415","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/01.RVI.0000167863.10122.2A","article-title":"A phase\u00a0I trial of alfimeprase for peripheral arterial thrombolysis","volume":"16","author":"Ouriel","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0420","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00126839-200809030-00006","article-title":"Alfimeprase","volume":"9","year":"2008","journal-title":"Drugs R D"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0425","unstructured":"Nuvelo, Inc.NUVO\u2010Nuvelo announces NAPA\u20102 data presentation webcast and conference call. Conference call transcript 24 January 2008."},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0430","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.2006.05.8438","article-title":"Phase\u00a0II trial of alfimeprase, a novel\u2010acting fibrin degradation agent, for occluded central venous access devices","volume":"24","author":"Moll","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0435","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2002.20.1.317","article-title":"Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial","volume":"20","author":"Deitcher","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0440","unstructured":"Nuvelo Inc. Nuvelo announces Phase\u00a02 SONOMA\u20103 trial did not meet target product profile and discontinues alfimeprase development. Media release: 17 March 2008."},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0445","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1161\/01.STR.0000182100.65262.46","article-title":"Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies","volume":"36","author":"Molina","year":"2005","journal-title":"Stroke"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0450","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12028-009-9204-1","article-title":"IV vs. IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study","volume":"11","author":"Sen","year":"2009","journal-title":"Neurocrit Care"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0455","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0735-1097(02)02067-3","article-title":"Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability","volume":"40","author":"Mehta","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0460","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/hs0302.104110","article-title":"Predictors of hemorrhagic transformation in patients receiving intra\u2010arterial thrombolysis","volume":"33","author":"Kidwell","year":"2002","journal-title":"Stroke"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0465","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/187152708784936635","article-title":"Targeting extracellular matrix proteolysis for hemorrhagic complications of tPA stroke therapy","volume":"7","author":"Wang","year":"2008","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0470","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tins.2008.09.006","article-title":"Tissue\u2010type plasminogen activator in the ischemic brain: more than a thrombolytic","volume":"32","author":"Yepes","year":"2008","journal-title":"Trends Neurosci"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0475","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt\u2010PA Stroke Study Group","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2009.03701.x_bb0480","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/01.WCB.0000137868.50767.E8","article-title":"The neurotoxicity of tissue plasminogen activator?","volume":"24","author":"Kaur","year":"2004","journal-title":"J Cereb Blood Flow Metab"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2009.03701.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622067356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622067356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2009.03701.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:51:01Z","timestamp":1761533461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622067356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1538783622067356"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03701.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03701.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}